

## KromaTiD, Inc

515 East Laurel Street  
Fort Collins, CO 80524

<b>Contact:</b>	Christopher Tompkins, President/CEO	<b>Email:</b>	ctompkins@kromatid.com
<b>Website:</b>	www.kromatid.com	<b>Founded:</b>	2007
<b>Telephone:</b>	303-819-5246	<b>Employees:</b>	5

## Description of Company:

KromaTiD's Genomic Single Strand Hybridization Platform is transforming chromosome imaging and opening new avenues for diagnosis of genetic diseases including cancers. In 2013, we are launching the first commercial platform for the routine discovery and detection of a recalcitrant class of DNA mutations: Chromosomal Inversions. Based on the GSSH platform, KromaTiD is launching a genome wide portfolio of research tools and building a pipeline of clinical diagnostic assays for sub-types of cancers, developmental disorders, and other genetic diseases.

## Market:

Reagent and kit sales in this market are greater than 500 million dollars per year and growing at greater than 20% per year. Our large and international customer base includes researchers from academia, government agencies, as well as the pharmaceutical, diagnostic and biotech industries. Diagnostic tests add tens of millions of dollars per indication to the total market for chromosome analysis assays.

KromaTiD's products include custom assays for specific research needs, inversion screening tools, biosimetry assays and research diagnostic assays for known, disease-causing inversions. KromaTiD has beta-tested inversion screening and discovery tools for chromosomes 3 and 10 and developed prototype diagnostic assays for two known sub-types of cancer. Using our proprietary probes, KromaTiD is also developing next generation FISH assays, improving the performance of traditional chromosome imaging. KromaTiD's products are market ready.

## Management:

- Christopher Tompkins, President and CEO. Former General Manager Proligo, LLC, manufacturer of DNA products and specialty assays. Over 15 years, pharmaceutical development, bioproducts and specialty research tools development, operations and executive experience.
- F. Andrew Ray, Research Head. Co-Inventor of the GSSH platform, former Los Alamos Radiation Biology Researcher Leader, Currently CSU faculty member.
- Terry Opgenorth, Board Chair. >20 years in biopharma R&D; former DVP, Drug Discovery, Abbott.

## Recent Milestones:

- KromaTiD has completed beta testing of its platform products and now offers genome wide custom assays in inversion detection and next gen FISH formats.
- KromaTiD received a NASA grant for assay development and funding from the Colorado Institute for Drug, Device and Diagnostic Development.

## Financing:

KromaTiD has received \$M in SBIR grants and other non-dilutive funding and \$150K in convertible debt from CID4. We are presently seeking investors for \$1M in seed funding followed by a \$5M Series A round. These funds will be used to launch our research tools portfolio to market and to build our pipeline of clinical diagnostic assays.